Vbi Vaccines Stock Working Capital
| VBIVQ Stock | 0.0005 0.0001 16.67% |
VBI Vaccines fundamentals help investors to digest information that contributes to VBI Vaccines' financial success or failures. It also enables traders to predict the movement of VBI Stock. The fundamental analysis module provides a way to measure VBI Vaccines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VBI Vaccines stock.
As of 12/26/2024, Net Working Capital is likely to grow to about (37.5 M). In addition to that, Change In Working Capital is likely to grow to about (9.5 M). VBI | Working Capital |
VBI Vaccines Company Working Capital Analysis
VBI Vaccines' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current VBI Vaccines Working Capital | (39.51 M) |
Most of VBI Vaccines' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VBI Vaccines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
VBI Capital Lease Obligations
Capital Lease Obligations |
|
As per the company's disclosures, VBI Vaccines has a Working Capital of (39.51 Million). This is 109.28% lower than that of the Healthcare sector and 107.33% lower than that of the Biotechnology industry. The working capital for all United States stocks is 102.67% higher than that of the company.
VBI Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VBI Vaccines' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VBI Vaccines could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics of similar companies.VBI Vaccines is currently under evaluation in working capital category among its peers.
VBI Fundamentals
| Revenue | 8.68 M | ||||
| Net Income | (92.84 M) | ||||
| Total Debt | 50.77 M | ||||
| Cash Flow From Operations | (60.88 M) | ||||
| Number Of Employees | 131 | ||||
| Total Asset | 86.95 M | ||||
| Retained Earnings | (582.45 M) | ||||
| Working Capital | (39.51 M) | ||||
| Net Asset | 86.95 M |
About VBI Vaccines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VBI Vaccines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VBI Vaccines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VBI Vaccines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with VBI Vaccines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VBI Vaccines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VBI Vaccines will appreciate offsetting losses from the drop in the long position's value.Moving together with VBI Stock
Moving against VBI Stock
| 0.53 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.48 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.44 | FBIOP | Fortress Biotech Pref | PairCorr |
| 0.39 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.37 | UPB | Upstream Bio, | PairCorr |
The ability to find closely correlated positions to VBI Vaccines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VBI Vaccines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VBI Vaccines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VBI Vaccines to buy it.
The correlation of VBI Vaccines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VBI Vaccines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VBI Vaccines moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VBI Vaccines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for VBI Stock Analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.